Revolution Medicines, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 191.31 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 41.00B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Details
| Name | Revolution Medicines, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 883 |
| Founded | 2014 |
| Ipo Date | 2020-02-13 |
| Ceo | Mark Goldsmith |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 17.00 |
| Isin | US76155X1000 |
| Cusip | 76155X100 |
| Cik | 1628171 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Mark A. Goldsmith M.D., Ph.D. | Chief Executive Officer, President and Chairman |
| Jack Anders | Chief Financial Officer |
| Margaret A. Horn J.D. | Chief Operating Officer |
| Jeffrey Cislini J.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | Senior Advisor |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder and Member of Scientific Advisory Board |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder and Member of Scientific Advisory Board |
| Walter Reiher Ph.D. | Chief Information Officer |
| Jan Smith Ph.D. | Chief Scientific Officer |
Contact
| Address | 700 Saginaw Drive, Redwood City, California 94063, United States |
| Phone | 650 481 6801 |
| Website | https://www.revmed.com |